berezko / iStockphoto.com
NPS Pharmaceuticals suffered a knock-back yesterday, when the US Court of Appeals for the Federal Circuit affirmed a decision which found that claims covering a patent owned by NPS were unpatentable.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Kyle Bass, Coalition for Affordable Drugs, PTAB, Gattex, NPS Pharmaceuticals, Shire, inter partes review, US Court of Appeals for the Federal Ciruit
